"Floxuridine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
| Descriptor ID |
D005467
|
| MeSH Number(s) |
D03.383.742.680.852.300.350 D13.570.230.430.432 D13.570.685.852.300.350
|
| Concept/Terms |
Floxuridine- Floxuridine
- 5-FUdR
- FUdR
- Fluorodeoxyuridine
- 5-Fluorodeoxyuridine
- 5 Fluorodeoxyuridine
|
Below are MeSH descriptors whose meaning is more general than "Floxuridine".
Below are MeSH descriptors whose meaning is more specific than "Floxuridine".
This graph shows the total number of publications written about "Floxuridine" by people in this website by year, and whether "Floxuridine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Floxuridine" by people in Profiles.
-
Yopp AC, Schwartz LH, Kemeny N, Gultekin DH, G?nen M, Bamboat Z, Shia J, Haviland D, D'Angelica MI, Fong Y, DeMatteo RP, Allen PJ, Jarnagin WR. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol. 2011 Aug; 18(8):2192-9.
-
Batist G, Gelmon KA, Chi KN, Miller WH, Chia SK, Mayer LD, Swenson CE, Janoff AS, Louie AC. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res. 2009 Jan 15; 15(2):692-700.
-
Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 2006 Jul; 5(7):1854-63.
-
Ter RB, Infantolino A, Leite LP, Ahtaridis G. Gastrointestinal ulceration and hemorrhage from hepatic arterial infusion chemotherapy. Gastrointest Endosc. 1999 Jan; 49(1):92.
-
Weiss AJ, Lackman RD. Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor: advantages and limitations. Am J Clin Oncol. 1997 Feb; 20(1):63-8.
-
Creaven PJ, Rustum YM, Petrelli NJ, Meropol NJ, Raghavan D, Rodriguez-Bigas M, Levine EG, Frank C, Udvary-Nagy S, Proefrock A. Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen. Cancer Chemother Pharmacol. 1994; 34(3):261-5.
-
Soulen MC, Weissmann JR, Sullivan KL, Lackman RD, Shapiro MJ, Bonn J, Weiss AJ, Gardiner GA. Intraarterial chemotherapy with limb-sparing resection of large soft-tissue sarcomas of the extremities. J Vasc Interv Radiol. 1992 Nov; 3(4):659-63.
-
Kashdan BJ, Sullivan KL, Lackman RD, Shapiro MJ, Bonn J, Weiss AJ, Gardiner GA. Extremity osteosarcomas: intraarterial chemotherapy and limb-sparing resection with 2-year follow-up. Radiology. 1990 Oct; 177(1):95-9.
-
Haurani FI, Kardinal CG, Biermann WA. Thymidylate synthetase and dihydrofolic acid reductase in the stimulated human lymphocyte. J Cell Physiol. 1978 Apr; 95(1):49-55.